Robert J. Motzer, MD:From his initial presentation, he originally presented with abdominal pain, which was found to be related to the diverticulitis. The metastatic kidney cancer was an incidental finding, which is now the most common way that kidney cancer is diagnosed. About 60% of patients at our center present with kidney cancer as an incidental finding.
One of the other features of this patient is the fact that in initial presentation he had a locally advanced disease, and with subsequent metastasis or relapse, within a year to 2 years. One of the problems, or the difficulties and challenges with this disease, is that there aren’t early warning signs for kidney cancer. So, about 25% of people will present with over metastasis at diagnosis, and another 30% of patients with localized disease will subsequently relapse. As a result, there’s a relatively large proportion of people diagnosed with kidney cancer that will ultimately need systemic therapy.
Good pathologic examination by pathologists is essential to type the kind of kidney cancer, to make sure it’s clear cell carcinoma. But beyond the morphology and the grade, there really isn’t any kind of standard biologic studies or biomarkers that are obtained on the kidney tumor that help us define treatment. There has been a high interest in studies for PD-L1 expression in kidney tumors, but for the most part they don’t exclude benefit with checkpoint inhibitors, and so they’re not used in standard management.
Transcript edited for clarity.
A Japanese-American Male With Recurrent RCC
November 2015
September 2017
July 2018
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Promising Results from Phase 1/2 Trial of NKT2152 for Advanced Kidney Cancer
September 20th 2024NKT2152, a novel oral HIF-2α inhibitor, showed promising results in treating advanced clear cell renal cell carcinoma, with an objective response rate of 20% in all-comers and 26.3% in the dose-escalation population.
Read More
GU Oncology Peers Explore Early Therapy Approaches in Low-Volume mRCC
September 19th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or low-volume favorable-risk metastatic clear cell renal cell carcinoma in the first article of a 2-part series.
Read More